quinazolines has been researched along with Experimental Hepatoma in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (25.00) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Das, D; Hong, J; Shi, J; Wang, J; Xie, L | 1 |
| Deng, J; Fan, X; Hao, X; Lei, F; Li, J; Liang, Y; Liang, Z; Liu, D; Shi, T; Wang, Z; Wen, H; Zhang, H | 1 |
| Gallez, B; Grégoire, V; Jordan, BF; Karroum, O; Kengen, J | 1 |
| Cao, D; Chen, L; Lei, L; Li, H; Ma, L; Tang, M; Wang, C; Wang, F; Wang, T; Wang, X; Xiang, W | 1 |
| Böhning, E; Calvisi, DF; Cigliano, A; Dombrowski, F; Evert, M; Günther, J; Merz, J; Peters, K; Pilo, MG; Ribback, S; Sailer, V; Steinmüller, F; Utpatel, K | 1 |
| Ansiaux, R; Dewever, J; Feron, O; Gallez, B; Grégoire, V; Jordan, BF | 1 |
| Aoudjehane, L; Barbu, V; Blivet-Van Eggelpoël, MJ; Chettouh, H; Desbois-Mouthon, C; Fartoux, L; Housset, C; Priam, S; Rey, C; Rosmorduc, O | 1 |
| Basaki, Y; Kuwano, M; Ogawa, K; Ono, M; Sakisaka, S; Ueda, S; Yoshie, M | 1 |
| Chen, SZ; Wang, SM; Zhang, JR | 1 |
| Stott, WT | 1 |
| Chao, Y; Chen, FD; Chi, KH; Chou, SL; Liu, RS; Wang, HE; Wang, YS; Yen, SH | 1 |
| Bartkowiak, J; Gaczyński, M; Kiliańska, Z; Krajewska, WM; Kłyszejko-Stefanowicz, L; Lipińska, A | 1 |
| Bunni, M; Dilwith, R; Galivan, J; Johnson, TB; Nair, MG; Priest, DG; Rhee, MS | 1 |
| Bunni, M; Chou, TC; Galivan, J; Johnson, TB; Nair, MG; Priest, D; Rhee, MS | 1 |
| Galivan, J; Nimec, Z; Rhee, M | 1 |
| Boschelli, D; Galivan, J; Kerwar, SS; Nimec, Z; Oronsky, AL; Rhee, M | 1 |
16 other study(ies) available for quinazolines and Experimental Hepatoma
| Article | Year |
|---|---|
In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Liver Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship | 2020 |
Design, synthesis and bioactivity study of evodiamine derivatives as multifunctional agents for the treatment of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Mice, Nude; Molecular Structure; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 2021 |
Tumor reoxygenation following administration of the EGFR inhibitor, gefitinib, in experimental tumors.
Topics: Animals; Cell Hypoxia; Electron Spin Resonance Spectroscopy; ErbB Receptors; Fibrosarcoma; Gefitinib; Liver Neoplasms, Experimental; Mice; Mice, Inbred C3H; Oximetry; Oxygen; Oxygen Consumption; Quinazolines | 2013 |
Synthesis, in vitro and in vivo evaluation of novel substituted N-(4-(2-(4-benzylpiperazin-1-yl)ethoxy)phenyl)-N-methyl-quinazolin-4-amines as potent antitumor agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms, Experimental; Mice; Mice, Nude; Molecular Docking Simulation; Molecular Structure; Piperazines; Quinazolines; Structure-Activity Relationship | 2016 |
The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Islets of Langerhans Transplantation; Liver Neoplasms, Experimental; Male; Nitrosamines; Protein Kinase Inhibitors; Quinazolines; ras Proteins; Rats; Rats, Inbred Lew; Sodium-Glucose Transporter 1; Thyroid Epithelial Cells; TOR Serine-Threonine Kinases; Transforming Growth Factor alpha | 2016 |
Decrease in tumor cell oxygen consumption after treatment with vandetanib (ZACTIMA; ZD6474) and its effect on response to radiotherapy.
Topics: Animals; Contrast Media; Electron Spin Resonance Spectroscopy; Liver Neoplasms, Experimental; Magnetic Resonance Imaging; Male; Mice; Neoplasm Transplantation; Oxygen Consumption; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2009 |
Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Division; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Female; Gefitinib; Glycoproteins; Hep G2 Cells; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms, Experimental; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, ErbB-3; Sorafenib; Xenograft Model Antitumor Assays | 2012 |
PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib.
Topics: Animals; Antineoplastic Agents; Cell Growth Processes; Chemokine CXCL1; Chemokines, CXC; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Dosage; Genes, erbB-1; Intercellular Signaling Peptides and Proteins; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2006 |
[Preparation of long-circulating nolatrexed dihydrochloride liposomes and its antitumor activity].
Topics: Animals; Antineoplastic Agents; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Liposomes; Liver Neoplasms, Experimental; Mice; Quinazolines | 2008 |
Regulatory implications of peroxisome proliferation: an industrial perspective.
Topics: Animals; Humans; Industry; Liver Neoplasms; Liver Neoplasms, Experimental; Microbodies; Quinazolines; Risk Assessment; Social Control, Formal; Species Specificity | 1996 |
Preclinical evaluation of locoregional delivery of radiolabeled iododeoxyuridine and thymidylate synthase inhibitor in a hepatoma model.
Topics: Animals; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Female; Humans; Idoxuridine; Iodine Radioisotopes; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Neoplasm Transplantation; Quinazolines; Rats; Rats, Sprague-Dawley; Thymidylate Synthase; Tumor Cells, Cultured | 2001 |
Nuclear proteins of hamster hepatoma after administration of antitumour agents.
Topics: Animals; Antimetabolites, Antineoplastic; Cricetinae; Depression, Chemical; Electrophoresis, Gel, Two-Dimensional; Electrophoresis, Polyacrylamide Gel; Gene Expression Regulation, Neoplastic; Liver Neoplasms, Experimental; Male; Mesocricetus; Methotrexate; Molecular Weight; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nuclear Proteins; Quinazolines; Testosterone | 1992 |
The role of cellular folates in the enhancement of activity of the thymidylate synthase inhibitor 10-propargyl-5,8-dideazafolate against hepatoma cells in vitro by inhibitors of dihydrofolate reductase.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line; Folic Acid; Folic Acid Antagonists; Kinetics; Liver Neoplasms, Experimental; Pyrimethamine; Quinazolines; Rats; Thymidylate Synthase; Trimetrexate | 1989 |
The enhancement of the activity of 10-propargyl-5,8-dideazafolate and 5,10-dideazatetrahydrofolate by inhibitors of dihydrofolate reductase.
Topics: Animals; Cell Line; Cell Survival; Folic Acid; Folic Acid Antagonists; Hypoxanthine; Hypoxanthines; Liver Neoplasms, Experimental; Quinazolines; Rats; Tetrahydrofolates; Thymidine; Tumor Cells, Cultured | 1989 |
Synergistic growth inhibition of rat hepatoma cells exposed in vitro to N10-propargyl-5,8-dideazafolate with methotrexate or the lipophilic antifolates trimetrexate or metoprine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Deoxyuridine; Folic Acid; Folic Acid Antagonists; Liver Neoplasms, Experimental; Methotrexate; Pyrimethamine; Quinazolines; Rats; Thymidine; Thymidylate Synthase; Trimetrexate | 1987 |
Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate.
Topics: Acyltransferases; Animals; Drug Synergism; Folic Acid; Folic Acid Antagonists; Hydroxymethyl and Formyl Transferases; Liver Neoplasms, Experimental; Phosphoribosylglycinamide Formyltransferase; Pyrimethamine; Quinazolines; Tetrahydrofolates; Thymidine Monophosphate; Trimetrexate; Tumor Cells, Cultured | 1988 |